Influence of Dyslipidemia on the Quality of Sexual Life in Women in the Menacme using a Combined Oral Contraceptive

Purpose Female sexual dysfunction is a complex and common condition that affects women, and the relationship between sexual function and dyslipidemia is poorly studied. This study aims to assess this relationship in the reproductive life women in the menacme who use combined oral contraceptives (COCs). Methods A total of 49 healthy women who were sexually active received COC pills that contained ethinylestradiol 30 mcg (EE30) plus levonorgestrel 150 mcg (LNG150). The women were divided into two groups according to their lipid profiles. Dyslipidemia was defined as a high-density lipoprotein (HDL) level < 50 mg/dL or a low-density lipoprotein (LDL) level > 130 mg/dL. Sexual function was assessed using the Female Sexual Function Index (FSFI) Questionnaire. Lipid and lipoprotein parameters were obtained at baseline and after the sixth cycle. Results After six cycles of the COCs, the total cholesterol and LDL cholesterol levels in the women with a LDL level > 130 mg/dL decreased by 14.7% and 22.1% respectively. In the women with a HDL level < 50 mg/dL at baseline, the HDL level increased by 15.5% at the end of the study. The arousal and orgasm domains and the FSFI total scores significantly increased in women with and without dyslipidemia. The desire and satisfaction domains increased only in the group without dyslipidemia at the end of the treatment period. Conclusions The EE30/LNG150 formulation increased the sexual function and it was only positively correlated with the HDL cholesterol level. These data indicated a low correlation between sexual function and the changes in the lipid and lipoprotein metabolism.

Download Full-text

ANALISIS HUBUNGAN KADAR GULA DARAH PUASA DENGAN KADAR KOLESTEROL HIGH DENSITY LIPOPROTEIN (HDL) PADA PASIEN DIABETES MELLITUS TIPE 2 DI RSUP SANGLAH

Meditory : The Journal of Medical Laboratory ◽

10.33992/m.v4i2.38 ◽

2016 ◽

Vol 4 (2) ◽

Author(s):

Nyoman Jirna

Keyword(s):

Blood Sugar ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Hdl Cholesterol ◽

Fasting Blood Sugar ◽

Cholesterol Levels ◽

Sugar Levels ◽

Dm Type 2 ◽

The Relationship

Abstract Diabetes mellitus (DM) is a group of metabolic diseases with characteristic hyperglycemia that happen by abnormal secretions of insulin, insulin action, or both. The condition of insulin resistance in DM type 2 cause abnormal lipid metabolism that indicated by increase or decrease levels of lipid fraction in plasma, include increase levels of Very Low Density Lipoprotein (VLDL) or triglycerides, decrease levels of High Density Lipoprotein (HDL), and formed small dense Low Density Lipoprotein (LDL). The purpose of this study is to determine the relationship between the fasting blood sugar levels with HDL cholesterol levels in patients with DM type 2. The method use an analytical study with cross sectional design. Sampling examined as many as 35 samples by purposive sampling. The relationship between fasting blood sugar levels with HDL cholesterol levels is analyzed by Pearson Product Moment Correlation test. Based on the result concluded that there is a relationship between fasting blood sugar levels with HDL cholesterol levels in patients with DM type 2 in RSUP Sanglah with significant value sig=0,030 (sig

Download Full-text

The effects of hormone implants on serum lipoproteins and steroid hormones in bilaterally oophorectomised women

Acta Endocrinologica ◽

10.1530/acta.0.1060116 ◽

1984 ◽

Vol 106 (1) ◽

pp. 116-120 ◽

Cited By ~ 38

Author(s):

E. Farish ◽

C. D. Fletcher ◽

D. M. Hart ◽

F. Al. Azzawi ◽

H. I. Abdalla ◽

...

Keyword(s):

High Density Lipoprotein ◽

Ldl Cholesterol ◽

Low Density Lipoprotein ◽

Lipoprotein Metabolism ◽

Density Lipoprotein ◽

Hdl Cholesterol ◽

Low Density ◽

Serum Lipoproteins ◽

Cholesterol Levels ◽

Transient Rise

Abstract. Serum lipoproteins were measured over a period of 6 months in 14 oophorectomised women treated with oestrogen implants (50 mg oestradiol-17β) and 17 oophorectomised women treated with oestrogen/testosterone implants (50 mg oestradiol-17β, 100 mg testosterone). Both types of implant caused only minimal changes in lipoprotein metabolism. Low density lipoprotein (LDL) cholesterol decreased with both types of implant and high density lipoprotein (HDL) cholesterol rose with the oestrogen implants. HDL subfractions were also measured. The oestrogen implants caused a transient rise in HDL2 cholesterol levels at 2 months and a slower rise in HDL3 cholesterol. The oestrogen/testosterone implants had no effect on HDL fractions. The results indicate that hormone implants do not cause the profound changes in lipoproteins associated with oral hormone therapy.

Download Full-text

Hepatic SRB1 (Scavenger Receptor Class B Type 1) Knockdown Reduces Atherosclerosis and Enhances the Antiatherosclerotic Effect of Brown Fat Activation in APOE*3-Leiden.CETP Mice

Arteriosclerosis Thrombosis and Vascular Biology ◽

10.1161/atvbaha.121.315882 ◽

2021 ◽

Author(s):

Enchen Zhou ◽

Zhuang Li ◽

Hiroyuki Nakashima ◽

Cong Liu ◽

Zhixiong Ying ◽

...

Keyword(s):

Low Density Lipoprotein ◽

Scavenger Receptor ◽

Lipoprotein Metabolism ◽

Density Lipoprotein ◽

Hdl Cholesterol ◽

Hepatic Uptake ◽

Brown Fat ◽

Cholesterol Levels ◽

Class B ◽

Atherosclerosis Development

Objective: Brown fat activation attenuates atherosclerosis development by accelerating triglyceride-rich lipoprotein turnover and/or stimulation of reverse cholesterol transport via the SRB1 (scavenger receptor class B type 1). The aim of this study was to investigate the specific role of hepatic SRB1 in the atheroprotective properties of brown fat activation. Approach and Results: APOE*3-Leiden.CETP mice, a well-established model of human-like lipoprotein metabolism and atherosclerosis, were treated with vehicle or adenoassociated virus serotype 8-short hairpin RNA, which decreased hepatic SRB1 protein levels by 40% to 55%. After 2 weeks, mice without or with hepatic SRB1 knockdown were treated with vehicle or the β3-adrenergic receptor agonist CL316 243 to activate brown fat for 4 weeks to determine HDL (high-density lipoprotein) catabolism and for 9 weeks to evaluate atherosclerosis. Surprisingly, hepatic SRB1 knockdown additively improved the beneficial effects of β3-adrenergic receptor agonism on atherosclerosis development. In fact, hepatic SRB1 knockdown per se not only increased HDL-cholesterol levels but also reduced plasma triglyceride and non-HDL-cholesterol levels, thus explaining the reduction in atherosclerosis development. Mechanistic studies indicated that this is due to increased lipolytic processing and hepatic uptake of VLDL (very low density lipoprotein) by facilitating VLDL-surface transfer to HDL. Conclusions: Hepatic SRB1 knockdown in a mouse model with an intact ApoE (apolipoprotein E)-LDLR (low density lipoprotein receptor) clearance pathway, relevant to human lipoprotein metabolism, reduced atherosclerosis and improved the beneficial effect of brown fat activation on atherosclerosis development, explained by pleiotropic effects of hepatic SRB1 knockdown on lipolytic processing and hepatic uptake of VLDL. Brown fat activation could thus be an effective strategy to treat cardiovascular disease also in subjects with impaired SRB1 function.

Download Full-text

Dyslipidaemia

The ESC Handbook on Cardiovascular Pharmacotherapy ◽

10.1093/med/9780198759935.003.0002 ◽

2019 ◽

pp. 33-48

Author(s):

Heinz Drexel

Keyword(s):

Cardiovascular Disease ◽

Randomized Clinical Trials ◽

Ldl Cholesterol ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Hdl Cholesterol ◽

Epidemiological Studies ◽

Residual Risk ◽

Atherosclerotic Cardiovascular Disease ◽

Cholesterol Levels

Lipid metabolism has gained cardiological interest only after statins were demonstrated to reduce cardiovascular disease in secondary and primary prevention. Therefore, this chapter first introduces the physiological and atherogenic properties of lipoproteins, before focusing on interventions. Both the efficacy and safety of statins have been proven in numerous randomized clinical trials. Because there is a considerable residual risk in statin-treated patients, additional approaches have been investigated. The focus is now on further reductions in low-density lipoprotein (LDL) cholesterol levels. First, high-intensity statin regimens were shown to reduce residual risk. Subsequently, ezetimibe was demonstrated, for the first time, to have a beneficial effect as a non-statin lipid intervention. More recently, inhibitors of the enzyme PCSK9 have demonstrated a very high efficacy in reducing LDL cholesterol levels. Although the causality of LDL for atherosclerotic cardiovascular disease has been proven in epidemiological studies, including Mendelian randomization studies, as well as interventional trials, adherence to statins and other therapies is far from optimal. In contrast, interventions to increase high-density lipoprotein (HDL) cholesterol levels could not proven to have further benefits when combined with statins.

Download Full-text

Paradoxical Hypercholesterolemia in an Otherwise Healthy Adult Man

Laboratory Medicine ◽

10.1093/labmed/lmz036 ◽

2019 ◽

Author(s):

Peter A Mcpherson

Keyword(s):

Cholesterol Level ◽

Total Cholesterol Level ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Hdl Cholesterol ◽

Red Yeast Rice ◽

Transfer Protein ◽

Cholesterol Levels ◽

Red Yeast ◽

High High Density Lipoprotein

AbstractHypercholesterolemia is characterized by serum cholesterol levels greater than 5 mmol per L. However, the distribution of cholesterol among lipoprotein classes has a significant bearing on diagnosis: high–low-density lipoprotein (LDL) cholesterol suggests familial hypercholesterolemia, whereas high–high-density lipoprotein (HDL) cholesterol is associated with hyperalphalipoproteinemia. On routine screening, a 23-year-old man presented with a total cholesterol level of 7.6 mmol per L but was subsequently found to have an HDL cholesterol level of 5.6 mmol per L. The clinical picture was confounded by his use of red yeast rice extract, a popular health supplement with hypolipidemic effects. In this case individual, the use of red yeast rice extract caused a hyperlipidemic state, ostensibly through downregulation of cholesteryl ester transfer protein. This case emphasizes the extended role of laboratory medicine in complex cases of hyperlipidemia.

Download Full-text

Pioglitazone-Mediated Changes in Lipoprotein Particle Composition Are Predicted by Changes in Adiponectin Level in Type 2 Diabetes

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/jc.2011-1699 ◽

2012 ◽

Vol 97 (1) ◽

pp. E110-E114 ◽

Cited By ~ 11

Author(s):

Susan Sam ◽

Steven Haffner ◽

Michael H. Davidson ◽

Ralph D'Agostino ◽

Alfonso Perez ◽

...

Keyword(s):

Risk Factors ◽

Cardiovascular Disease ◽

Particle Size ◽

Adiponectin Level ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Hdl Cholesterol ◽

Vldl Particle ◽

The Relationship

Context: In animal and observational studies, adiponectin is associated with lipoprotein risk factors for cardiovascular disease. Objective: We analyzed data from a randomized clinical trial to evaluate the relationship between changes in adiponectin to changes in lipoprotein risk factors after an intervention that alters adiponectin levels. Design and Setting: Adiponectin levels were measured at baseline and follow-up, as were lipoprotein risk factors for cardiovascular disease, at academic medical centers and ambulatory care centers. Patients and Other Participants: Participants included 361 men and women with type 2 diabetes. Intervention: Intervention included randomization to treatment with glimepiride or pioglitazone for 72 wk. Main Outcome Measure: The relationship of treatment-related differences in adiponectin level to treatment-related differences in lipoprotein cardiovascular risk factors at 72 wk was evaluated. Results: Pioglitazone led to an increase in adiponectin compared with glimepiride. Compared with baseline, pioglitazone treatment at 72 wk led to an increase in low-density lipoprotein (LDL) and high-density lipoprotein (HDL) particle size and a decrease in very-low-density lipoprotein (VLDL) particle size and LDL particle number. Glimepiride treatment more modestly decreased LDL particle number and increased LDL particle size. At 72 wk, there were significant treatment group differences for HDL, LDL, and VLDL particle size, and triglyceride and HDL cholesterol level. The increase in adiponectin predicted treatment-related improvement for triglyceride and HDL cholesterol level and LDL and HDL particle size. Conclusion: Increased adiponectin contributed to treatment-related benefit in lipoprotein cardiovascular disease risk factors in obese diabetic subjects treated with pioglitazone. These results provide support for a model that mechanistically links changes in adiponectin level to changes in lipoprotein composition in humans.

Download Full-text

Increased levels of high-density lipoprotein cholesterol are ineffective in inhibiting the development of immune responses to oxidized low-density lipoprotein and atherosclerosis in transgenic rabbits expressing human apolipoprotein (apo) A-I with severe hypercholesterolaemia

Clinical Science ◽

10.1042/cs1000343 ◽

2001 ◽

Vol 100 (3) ◽

pp. 343-355 ◽

Cited By ~ 2

Author(s):

Agnès BOULLIER ◽

Nathalie HENNUYER ◽

Anne TAILLEUX ◽

Christophe FURMAN ◽

Nicolas DUVERGER ◽

...

Keyword(s):

High Density Lipoprotein ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Hdl Cholesterol ◽

Ldl Oxidation ◽

Low Density ◽

Human Apolipoprotein ◽

Cholesterol Levels ◽

Immunological Markers ◽

Transgenic Rabbits

High levels of high-density lipoprotein (HDL) cholesterol have been reported to protect against the development of atherosclerosis in humans by increasing reverse cholesterol transport and inhibiting the oxidation of low-density lipoprotein (LDL) due to the paraoxonase content of HDL. The purpose of the present study was to assess if there are any relationships between in vivo increases in serum levels of immunological LDL oxidation markers [autoantibodies against oxidized LDL, autoantibodies against malondialdehyde-modified LDL, LDL immune complexes and anti-cardiolipin autoantibodies], paraoxonase activity and the development of atherosclerosis in control rabbits and in transgenic rabbits expressing human apolipoprotein (apo) A-I. A total of 13 apo A-I transgenic rabbits and 18 non-transgenic littermates were fed on a cholesterol-rich diet (0.4%, w/w) for 14 weeks, and were monitored at weeks 0, 2, 6, 10 and 14. Aortic atherosclerotic lesions were measured at the end of this period. Human apo A-I transgenic rabbits with high HDL cholesterol levels were not protected against the development of atherosclerosis when they were fed on a cholesterol-rich diet which induced dramatic hypercholesterolaemia. Immunological markers of LDL oxidation increased and serum paraoxonase activity decreased similarly in control and transgenic rabbits. In conclusion, the present study demonstrates that high HDL cholesterol levels are ineffective in inhibiting increases in immunological markers of LDL oxidation and the development of atherosclerosis in a mammal with severe hypercholesterolaemia.

Download Full-text

ANGPTL3 Levels in Healthy and Mild Preeclamptic Pregnant Women

Journal of the Endocrine Society ◽

10.1210/jendso/bvab048.1518 ◽

2021 ◽

Vol 5 (Supplement_1) ◽

pp. A747-A747

Author(s):

Maria F Garces ◽

Roberto Franco - Vega ◽

Luis M Maldonado - Acosta ◽

Andres Castro - Pinzón ◽

Javier Eslava-Schmalbach ◽

...

Keyword(s):

Pregnant Women ◽

Low Density Lipoprotein ◽

Lipoprotein Metabolism ◽

Density Lipoprotein ◽

Study Groups ◽

Normal Pregnancy ◽

Lipoprotein Cholesterol ◽

Fed State ◽

The Third ◽

Cholesterol Levels

Abstract Introduction: Throughout normal pregnancy, different metabolic and hormonal adaptations are presented, among others, significant modifications in the profile of lipids and lipoprotein metabolism. On the other hands, Angiopoietin-like protein 3 (ANGPTL3) are involved in the regulation of triglyceride metabolism in the fed state by inhibiting the enzyme lipoprotein lipase in oxidative tissues. Objective: Thus, the objective of this study was to determine the profile of serum ANGPTL3 levels during three periods of gestation and three months after delivery. Design, setting and Participants: Serum ANGPTL3 levels were analyzed by ELISA, throughout pregnancy in a case-control study nested within a longitudinal prospective cohort of healthy pregnant (n = 52) and mild preeclamptic women (n = 20), women in the third month postpartum (n = 20) and healthy non-pregnant women (n = 20). The results obtained were correlated with biochemical, hormonal, and anthropometric variables. Results: A significant reduction in ANGPTL3 levels was observed from the first to the third trimesters of pregnancy in healthy and preeclamptic pregnant women when compared with healthy non-pregnant and postpartum women (p<0.01). There were no significant differences in serum ANGPTL3 levels between normal and preeclamptic women. Serum ANGPTL3 levels were positively correlated with triglyceride, very-low-density lipoprotein cholesterol, and total cholesterol levels in healthy non-pregnant (p<0.05); whereas there were no significant correlations between ANGPTL3 with the same variables in healthy and preeclamptic pregnant women. Besides, there were no significant correlations between serum ANGPTL3 with body mass index, high-density lipoprotein cholesterol, glucose, insulin, leptin or HOMA-IR in the study groups described above. Conclusions: The results of the present study show for the first time that ANGPTL3 could be playing a fundamental role in the homeostasis of lipid metabolism throughout gestation. Thus, low levels of ANGPTL3 during pregnancy might favor the accumulation of lipid in oxidative tissues as a deposit of maternal energy source, while preserving glucose and amino acids for the fetus.

Download Full-text

On the Severity of Carpal Tunnel Syndrome: Metabolic Syndrome or Obesity

Open Access Macedonian Journal of Medical Sciences ◽

10.3889/oamjms.2020.5273 ◽

2020 ◽

Vol 8 (A) ◽

pp. 606-610

Author(s):

Angelo Vasiliadis ◽

George Charitoudis ◽

Theofanis Kantas ◽

George Giovanidis ◽

George Biniaris

Keyword(s):

Metabolic Syndrome ◽

Waist Circumference ◽

Low Density Lipoprotein ◽

Fasting Blood Glucose ◽

Density Lipoprotein ◽

Low Density Lipoprotein Cholesterol ◽

Cholesterol Levels ◽

Tunnel Syndrome ◽

The Mean ◽

The Relationship

AIM: This study aimed to determine the relationship between CTS, metabolic syndrome and obesity and to compare the severity of CTS between patients with or without metabolic syndrome (MS) and patients with or without obesity. METHODS: In this prospective study, patients with clinical and electrophysiological confirmed diagnosis of CTS were included. The waist circumference, blood pressure, fasting blood glucose, fasting triglycerides and high/low density lipoprotein cholesterol levels were recorded. Patients were categorized having metabolic syndrome according to Adult Treatment Panel III definition, while body mass index was used to identify obesity. RESULTS: A total of 65 patients with a mean age of 58.91 ± 12.49 years were included. MS was found in 39 (60%) patients and obesity in 27 (41.5%) patients. The CTS was described as mild, moderate and severe in 8, 12 and 19 hands of those with MS and in 2, 6, and 18 of those without MS respectively (p = 0.207). There were no statistically significant results observed between BMI and the severity of CTS (p > 0.05). The mean waist circumference was 94.75 ± 7.36, 98.78 ± 9.64, 106.42 ± 10.78, 86.41 ± 6.77 for patients with MS+_O–, MS–O+_, MS+_O+_ _and MS–O– _respectively (p < 0.002). CONCLUSION: CTS appears to be more severe in patients with MS than in patients with obesity. Central obesity is one of the well-known risk factors for CTS, but components of MS may have a greater effect on the severity of CTS.

Download Full-text

High Triglyceride/HDL Cholesterol Ratio is Associated with Silent Brain Infarcts in a Healthy Population

10.21203/rs.2.9432/v2 ◽

2019 ◽

Author(s):

Ki-Woong Nam(Former Corresponding Author) ◽

Hyung-Min Kwon(New Corresponding Author) ◽

Han-Yeong Jeong ◽

Jin-Ho Park ◽

Hyuktae Kwon ◽

...

Keyword(s):

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Vascular Diseases ◽

Hdl Cholesterol ◽

Cerebrovascular Diseases ◽

Healthy Population ◽

Cholesterol Ratio ◽

Silent Brain Infarct ◽

Cholesterol Levels

Abstract Background: Triglycerides (TG)/high-density lipoprotein (HDL) cholesterol ratio is a marker of small/dense low-density lipoprotein particles, which are closely associated with various metabolic and vascular diseases. However, the role of TG/HDL cholesterol ratio in cerebrovascular diseases has not been well studied. In this study, we evaluated the relationship between TG/HDL cholesterol ratio and the presence of silent brain infarct (SBI) in a neurologically healthy population. Methods: We retrospectively evaluated consecutive participants in health check-ups between January 2006 and December 2013. SBI was defined as an asymptomatic, well-defined lesion with a diameter of ≥ 3 mm on T1- or T2-weighted images. TG/HDL cholesterol ratio was calculated after dividing absolute TG levels by absolute HDL cholesterol levels. Results: Of 3,172 healthy participants, 263 (8.3%) had SBI lesions. In multivariate analysis, TG/HDL cholesterol ratio was independently associated with SBI (adjusted odds ratio [aOR] = 1.16, 95% confidence interval [CI] = 1.00 to 1.34, P = 0.047). This association was prominent in males (aOR = 1.23, 95% CI = 1.03 to 1.48, P = 0.021), but not in females. In the analyses of the relationships between lipid parameters and SBI lesion burden, TG/HDL cholesterol ratio was positively correlated, and total cholesterol/TG ratio was negatively correlated with SBI lesion burden, in dose-response manners (P for trend = 0.015 and 0.002, respectively). Conclusions: The TG/HDL cholesterol ratio was positively associated with the prevalence of SBI in a neurologically healthy population.

Download Full-text